Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

In other deals, Linklaters, Willkie and Latham are advising as PAI Partners negotiates to buy a stake in Alvest, a France-based provider of ground support equipment for airports, in a deal worth an ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our ...

L'Oreal said it would sell a 2.3% stake, or about 29.6 million shares for 101.5 euros each, back to the pharma company. After the sale, L'Oreal will hold 7.2% of Sanofi's share capital and 13.1% of ...

The beauty giant said the transaction – selling approximately 29.6 million of its Sanofi shares for €101.5 per share – will ...

L'Oreal said it would sell a 2.3% stake in Sanofi. "L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion," at 0709 GMT, incorrectly said the beauty company was selling 2.3% of its stake ...

Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings ...

Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...